Apricoxib
- Generic Name
- Apricoxib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20N2O3S
- CAS Number
- 197904-84-0
- Unique Ingredient Identifier
- 5X5HB3VZ3Z
- Background
Apricoxib has been used in trials studying the treatment and prevention of Lung Cancer, Breast Cancer, Pancreatic Cancer, Non Small Cell Lung Cancer, and Metastatic Pancreatic Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer
- First Posted Date
- 2012-02-14
- Last Posted Date
- 2020-09-22
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT01532362
- Locations
- ๐บ๐ธ
Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 109
- Registration Number
- NCT00771953
- Locations
- ๐บ๐ธ
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
๐บ๐ธWest Virginia University Clinical Trials Research Unit, Morgantown, West Virginia, United States
๐บ๐ธMercy Research Institute, Miami, Florida, United States
APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2012-11-07
- Lead Sponsor
- Tragara Pharmaceuticals, Inc.
- Target Recruit Count
- 109
- Registration Number
- NCT00709826
- Locations
- ๐บ๐ธ
The Queen's Medical Center Cancer Center, Honolulu, Hawaii, United States
๐บ๐ธFront Range Cancer Specialists, Ft. Collins, Colorado, United States
๐บ๐ธBronx River Medical Associates, P.C., Bronx, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.